Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Ting Pan *Department of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0009-0004-8225-3104
Jiamei Zhu *Department of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0009-0003-5230-3740
Xuyan Wang *Department of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0009-0002-3090-0459
Dekun Tang *Department of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0009-0008-4599-5570
Ziming WangDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0009-0005-0488-1292
Yunqiao YangDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0009-0008-4670-5168
Yin TengGuizhou Institute of Precision Medicine, Affiliated Hospital of Guizhou Medical University, Guiyang, China.ORCID 0009-0000-4326-205X
Qianting TianDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0009-0000-0913-5305
Guixue DanDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0009-0005-1003-9069
Chaochun ChenDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0000-0002-1028-1331
Dafang YuDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0009-0001-8490-0596
Mengyuan LiuDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0009-0005-2234-989X
Houmei WangDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0000-0003-1739-1338
Tuo ZhangDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0000-0003-3256-5930
Bing GuoDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0000-0001-8998-2597
Tengxiang ChenDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0000-0001-6907-1374
Bangming JinDepartment of Physiology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.ORCID 0009-0009-1442-7535
Funding
Guizhou Medical University (GMU) [2022]106Guizhou Provincial Basic Research Program (Natural Science) ZD[2025]061Guizhou Provincial Key Technology R&D Program Project [2023]191National Natural Science Foundation of China (NSFC) 32160144National Natural Science Foundation of China (NSFC) 82060444Natural Science Foundation of Guizhou Province (Guizhou Natural Science Foundation) [2021]4029Natural Science Foundation of Guizhou Province (Guizhou Natural Science Foundation) [2022]4017Natural Science Foundation of Guizhou Province (Guizhou Natural Science Foundation) [2024]327Postgraduate Research Fund Project 2024YJSKYJJ268Postgraduate Research Fund Project 2024YJSKYJJ302
6 · The paper itself
Abstract
Ferroptosis is a characteristic form of cell death triggered by excessive iron-dependent reactive oxygen species (ROS) that plays an important role in suppressing tumor development. In this study, we identified MEN1 as a driver of ferroptosis in lung cancer. MEN1 facilitated lipid ROS generation and sensitized lung cancer cells to ferroptosis by perturbing CD44 precursor messenger RNA splicing. CD44 variant isoforms were highly expressed and correlated with poor prognosis in human lung cancers. Loss of Men1 profoundly accelerated the progression of mutant Kras-driven lung adenocarcinoma and promoted the accumulation of CD44 variant isoforms. Mechanistically, MEN1 maintained a relatively slow RNA polymerase II elongation by controlling the release of PAF1 from the CD44 precursor messenger RNA, which in turn prevented the inclusion of CD44 variable exons. Furthermore, CD44 variable exon 6-interfering peptides effectively abrogated the growth and metastasis of established MEN1-deficient tumors by activating ferroptosis. Collectively, this study unveils a mechanism of tumor suppression based on MEN1 regulation of CD44 alternative splicing, ROS production, and ferroptosis induction. SIGNIFICANCE: MEN1 governs CD44 alternative splicing and CD44 variant generation to activate ferroptosis and disrupt lung cancer development, highlighting the potential of targeting this axis to treat MEN1-deficient tumors.
Indexed as
Adenocarcinoma of LungAlternative SplicingFerroptosisHyaluronan ReceptorsLung NeoplasmsProto-Oncogene ProteinsAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceReactive Oxygen SpeciesCD44 protein, humanHyaluronan ReceptorsProto-Oncogene ProteinsReactive Oxygen Species
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
MEN1 Promotes Ferroptosis by Disrupting CD44 Alternative Splicing to Suppress Lung Cancer. · full record | OpenQuestion